PNS232 What Constitutes the VALUE of Patient Engagement in the Development of New Medicines? Development of the Paradigm Monitoring and Evaluation Framework

Robinson, Paul D.; Finlay, Teresa; Fruytier, Sevgi E.; Schuitmaker-Warnaar, Tjerk Jan

doi:10.1016/j.jval.2020.08.1676

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several UK guidelines, frameworks and governances in place to facilitate and guide the integration and reporting of meaningful PPI in health research 22–26. Given the growing focus on meaningful PPI within pharmaceutical medicines development, there have been recent initiatives to develop frameworks specifically for the pharmaceutical industry 27–29…”

Section: Introductionmentioning

confidence: 99%

“…[22][23][24][25][26] Given the growing focus on meaningful PPI within pharmaceutical medicines development, there have been recent initiatives to develop frameworks specifically for the pharmaceutical industry. [27][28][29] Within Pfizer UK, the Patient Focused Medicines Development (PFMD) Patient Engagement Quality Guidance (PEQG) tool 30 has emerged as a standard internal benchmark for PPI work for self-reflection and to recommend future ways of working. The preference for the PEQG tool is based on the robust process that went into designing it, specifically with medicines development in mind.…”

Section: Introduction Patient and Public Involvement In Health Researchmentioning

confidence: 99%

See 1 more Smart Citation

Characterising meaningful patient and public involvement in the pharmaceutical industry research setting: a retrospective quality assessment

Dews,

Bassi,

Buckland

et al. 2023

BMJ Open

View full text Add to dashboard Cite

ObjectivesPatient and public involvement (PPI) in clinical research has a well-established infrastructure in the UK, and while there has been good progress within pharmaceutical-industry-sponsored research, further improvements are still needed. This review aims to share learnings from quality assessments of historical PPI projects within Pfizer UK to inform future projects and drive PPI progress in the pharmaceutical industry.Design and settingInternal assessments of Pfizer UK PPI projects were conducted to identify all relevant projects across the medicines development continuum between 2017 and 2021. Five sample projects were developed into case studies.Outcome measureRetrospective quality assessments were performed using the Patient Focused Medicines Development (PFMD) Patient Engagement Quality Guidance (PEQG) tool. Recommendations for improvement were developed.ResultsRetrospective case study analysis and quality framework assessment revealed benefits of PPI to both Pfizer UK and to external partners, as well as challenges and learnings to improve future practice. Recommendations for improvement based on these findings focused on processes and procedures for PPI, group dynamics and diversity for PPI activities, sharing of expertise, the importance of bidirectional and timely feedback, and the use of understandable language in materials.ConclusionsPPI in medicines development is impactful and beneficial but is still being optimised in the pharmaceutical industry. Using the PFMD PEQG tool to define gaps, share learnings and devise recommendations for improvement helps to ensure that PPI is genuine and empowering, rather than tokenistic. Ultimately, these recommendations should be acted on to further embed PPI as an integral part of medicines development and health research within the pharmaceutical industry. This article includes a plain language summary in the supplement.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introduction Patient and Public Involvement In Health Researchmentioning

confidence: 99%

Characterising meaningful patient and public involvement in the pharmaceutical industry research setting: a retrospective quality assessment

Dews,

Bassi,

Buckland

et al. 2023

BMJ Open

View full text Add to dashboard Cite

show abstract

PNS232 What Constitutes the VALUE of Patient Engagement in the Development of New Medicines? Development of the Paradigm Monitoring and Evaluation Framework

Cited by 1 publication

References 0 publications

Characterising meaningful patient and public involvement in the pharmaceutical industry research setting: a retrospective quality assessment

Characterising meaningful patient and public involvement in the pharmaceutical industry research setting: a retrospective quality assessment

Contact Info

Product

Resources

About